"The research collaboration will investigate the ability of investigational compound PBT434 to mitigate gastrointestinal dysfunction; constipation, lowered colon motility and inflammation in mouse models, including an alpha-synuclein transgenic mouse."

"PBT434 is the first of a new generation of small molecules from the quinazolinone class of drugs that was specifically designed to block the accumulation and aggregation of alpha-synuclein and is expected to begin human testing in a Phase 1 trial later this year."

Press release from Prana:
Prana commences research collaboration with Takeda for the treatment of Parkinson’s disease gastrointestinal neuropathology | Prana Biotechnology

Open-access research paper:
The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease | Acta Neuropathologica Communications | Full Text